Compositions and methods for identifying altered effectiveness of beta blocker therapy
The present invention provides a method of identifying a human subject as having an increased risk of altered effectiveness of beta blocker therapy, comprising detecting in the subject one or more single nucleotide polymorphism associated with increased risk of altered effectiveness of beta blocker therapy.
1. A method of identifying and treating a subject having an increased risk of an altered effectiveness of beta blocker therapy to prevent/ameliorate postoperative atrial fibrillation during and/or after coronary artery bypass grafting surgery, comprising:
a) obtaining a nucleic acid sample from a subject undergoing coronary artery bypass grafting surgery;
b) detecting in the nucleic acid sample of the subject the presence of:
i) an A allele at single nucleotide polymorphism rs3740563;
ii) an A allele at single nucleotide polymorphism rs4752292;
iii) an A allele at single nucleotide polymorphism rs11198893;
iv) an A allele at single nucleotide polymorphism rs10787959; or
v) any combination of (i) through (iv) above;
c) identifying the subject as having an increased risk of altered effectiveness of beta blocker therapy; and
d) administering treatment to said subject identified in step c) as having an increased risk of altered effectiveness of beta blocker therapy, wherein the treatment comprises administration of a nondihydropiridine calcium channel blocker and/or amiodarone to prevent/ameliorate postoperative atrial fibrillation, during and/or after coronary artery bypass grafting surgery.
2. The method of claim 1 , wherein the detecting step consists of detecting the presence of an A allele at single nucleotide polymorphism rs3740563 and an A allele at rs4752292.
3. The method of claim 1 , wherein the nondihydropiridine calcium channel blocker and/or amiodarone is administered to the subject preoperatively, perioperatively, and/or postoperatively.
4. The method of claim 1 , wherein the nondihydropiridine calcium channel blocker and/or amiodarone is administered intravenously.
5. The method of claim 1 , wherein the nondihydropiridine calcium channel blocker and/or amiodarone is administered to the subject perioperatively and/or postoperatively.
6. The method of claim 1 , wherein the nondihydropiridine calcium channel blocker and/or amiodarone is administered to the subject postoperatively.
7. The method of claim 1 , wherein the treatment comprises administration of a nondihydropiridine calcium channel blocker.
8. The method of claim 7 , wherein the nondihydropiridine calcium channel blocker comprises diltiazem.
9. The method of claim 1 , wherein the treatment comprises administration of amiodarone.
10. The method of claim 1 , wherein the detecting comprises nucleic acid amplification and/or sequencing.